Clinical Research Of Tianmeng Oral Liquid Joint Paroxetine Treatment To Poststoke Comorbid Anxiety And Depression In Kidney Deficiency

Objective：This study is to reevaluate the clinical efficacy and safety of TianMengOral Liquid to treat PSCAD, based on the clinical application and the researchformerly. In order to lay the foundation of further expanded application of TianMengOral,We assess the clinical efficacy of TianMeng Oral Liquid Joint Paroxetinecomprehensively and objectively by the following methods, such as observing thescale of HAMD-17, the scale of HAMA-14, the scale of syndromes and NIHSS。Methods：We Choose sixty patients according with PSCAD diag-nosis standard, whosatisfying the following requirement, for instance, does not exist severe barrier-freeof conscious、ve-rbal function obstacle and dysarthria，by a randomized, standardcontrol design method, then assign thirty patients to treatment gr-oup and other thirtyto control group respectively, using random number list. Based on the routinetreatment of Cerebrovascular disease, We use TianMeng Oral Liquid Joint Paroxetineor Paroxetine to cure the patients respectively for four weeks. The instructions of theTianMeng Oral are2times a day,20ml at a time,；Paroxetine（1times a day，20mg ata time）.We should evaluate the HAMA-14、HAMD-17before and after experiment.We should judge the syndromes of stroke and detect the change of NIHSS before andafter the test. We should also inspect ALT、AST、BUN、Cr and observe the adversereactions and record it timely.Statistical data will be collected by spss17.0.Result：The patients of the two groups are comparable (P>0.05)in the followingaspects, namely, gender, nationality, cultural degree, course of disease, concomitantdiseases.The four curative effects are as follows:1. HAMA and HAMD score:(1)Compared the two groups before treatment, statisticsprocessing has no significant difference (P>0.05).(2)two groups,statistics processinghas significant difference before and after treatment (P <0.05).(3)there werestatistically significant difference beteween the two groups after treatment (P <0.05). Which prompt that TianMeng Oral Liquid Joint Paroxetine more better thanParoxetine.2.TCM syndromes score:(1)Compared the two groups before treatment, statisticsprocessing has no significant difference (P>0.05).(2)the control group has nostatistical difference before and after treatment (P>0.05), but statistics processinghas significant difference in the treatment group (P <0.05).(3)there were statisticallysignificant difference beteween the two groups after treatment (P <0.05). Whichprompt that TianMeng Oral can improve TCM syndromes integrals.3.NIHSS score:(1)Compared the two groups were not significant difference beforetreatment (P>0.05).(2)two groups,statistics processing has significant differencebefore and after treatment (P <0.05).(3)there were statistically significant differencebeteween the two groups after treatment (P <0.05). indicating that TianMeng OralLiquid Joint Paroxetine more effective in improving patients’ Neurological functionthan Paroxetine.4.there is no serious adverse reactions between treatment group and control groupduring treatment.Conclusion：TianMeng Oral Liquid Joint Paroxetine more effective in improving theClinical symptoms of PSCAD patients, effectively improve TCM syndrome,promtethe Neurological function；TianMeng Oral has a good safety in the Treatment ofPSCAD。...